Topics

UCB acquires Ra Pharma for $2.1bn to enrich its rare disease portfolio

06:30 EDT 11 Oct 2019 | Pharmaceutical Technology

UCB has acquired Massachusetts-based Ra Pharmaceuticals for $48 per share, bringing the total transaction to a value of approximately $2.1bn....
Read More...

The post UCB acquires Ra Pharma for $2.1bn to enrich its rare disease portfolio appeared first on Pharmaceutical Technology.

Original Article: UCB acquires Ra Pharma for $2.1bn to enrich its rare disease portfolio

NEXT ARTICLE

More From BioPortfolio on "UCB acquires Ra Pharma for $2.1bn to enrich its rare disease portfolio"

Quick Search

Relevant Topic

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...